LI-RADS v2018在钆塞酸增强MRI上检测肝移植候选者肝细胞癌的表现欠佳
回顾性纳入2019年1月至2020年12月接受钆塞酸增强MRI并后续行肝切除或肝移植的肝癌患者281例,比较LI-RADS v2018 LR-5的敏感度和特异度。肝移植组每患者敏感度48.5% vs 肝切除组79.6%,每病灶敏感度31.0% vs 75.9%,均显著更低;特异度无显著差异。米兰标准患者分配准确率为50.0%。
要点
- 肝移植候选者中LI-RADS v2018 LR-5的每患者敏感度48.5%、每病灶敏感度31.0%,均低于肝切除患者。
- 两组每患者和每病灶特异度均无显著差异(肝移植组均为100.0%,肝切除组91.7%和94.1%)。
- 病灶更小、病灶数目更多、Child-Pugh评分更高的患者,LI-RADS敏感度显著更低。
核心结论
- LI-RADS v2018在钆塞酸增强MRI上对肝移植候选者可能不够充分,对于存在显著临床因素的患者应考虑其他诊断影像检查。
研究设计与样本
- 回顾性研究,纳入2019年1月至2020年12月接受钆塞酸增强MRI并后续行肝切除或肝移植的肝癌患者281例,其中肝切除组237例、肝移植组44例。
诊断标准与关键数值
- 以LI-RADS v2018 LR-5为诊断标准,肝移植组每患者敏感度48.5%、每病灶敏感度31.0%,每患者特异度100.0%、每病灶特异度100.0%;肝切除组每患者敏感度79.6%、每病灶敏感度75.9%,每患者特异度91.7%、每病灶特异度94.1%。
临床应用与阅片要点
- 在肝移植候选者中,若病灶更小、病灶数目更多或Child-Pugh评分更高,LI-RADS v2018的敏感度显著更低;作者认为此时其他影像检查可能有助于确定移植资格。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the diagnostic performance for hepatocellular carcinoma (HCC) detection of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 on gadoxetic acid-enhanced MRI, comparing liver transplant candidates (LT group) with patients who underwent surgical resection (SR group), and to determine significant clinical factors for diagnostic performance of LI-RADS v2018.
METHODS: Patients who underwent gadoxetic acid-enhanced MRI and subsequent SR or LT for HCC were retrospectively included between January 2019 and December 2020. The sensitivity and specificity of LI-RADS LR-5 for HCC were compared between the two groups using generalized estimating equations. The accuracy of patient allocation according to the Milan criteria was calculated for the LT group. Univariable and multivariable logistic regression analyses were performed to determine significant clinical factors associated with the sensitivity of LI-RADS.
RESULTS: Of the 281 patients, 237 were assigned to the SR group, and 44 were assigned to the LT group. The LT group showed significantly lower per-patient (48.5% vs. 79.6%, p < .001) and per-lesion sensitivity (31.0% vs. 75.9%, p < .001) than the SR group, whereas no significant difference in both per-patient (100.0% vs. 91.7%, p > .99) and per-lesion specificities (100.0% vs. 94.1%, p > .99). The accuracy of patient allocation was 50.0%. Sensitivity was significantly lower in patients with a smaller lesion size (p < .001), a larger lesion number (p = .002), and a higher Child-Pugh score (p = .009).
CONCLUSION: LI-RADS v2018 on gadoxetic acid-enhanced MRI might be insufficient in liver transplant candidates and other diagnostic imaging tests should be considered in patients with these significant clinical factors.
CLINICAL RELEVANCE STATEMENT: In liver transplant candidates with a smaller lesion size, a larger lesion number, and a higher Child-Pugh score, imaging tests other than gadoxetic acid-enhanced MRI may be clinically useful to determine the transplant eligibility.
KEY POINTS: • The sensitivity of the Liver Imaging Reporting and Data System (LI-RADS) was lower in liver transplant candidates than in those who underwent surgical resection. • With the use of gadoxetic acid-enhanced MRI, the accuracy of patient allocation for liver transplantation on the basis of the Milan criteria was suboptimal. • The sensitivity of LI-RADS v2018 was significantly associated with lesion size, lesion number, and Child-Pugh classification.
引用
- Oh NE, Choi SH, Kim S, et al. Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates. Eur Radiol. 2023. PMID: 37532900. doi:10.1007/s00330-023-10014-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。